A Phase 1/2 interventional study of Belantamab mafodotin and Nirogacestat in Multiple Myeloma, sponsored by GlaxoSmithKline. Active, not recruiting at 12 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-16.
Sponsored by GlaxoSmithKline · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 49 studies testing belantamab mafodotin in Multiple Myeloma — 15 open to participants now, 35 under way, 8 of them phase 3. belantamab mafodotin · Multiple Myeloma.
Among the 49 studies testing belantamab mafodotin in Multiple Myeloma, this one is the 35th largest by enrollment, is one of 10 that started in 2022, is one of 17 in phase 1/2, reaches primary completion later than 8 of the 34 other live ones, and was the 40th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →15 of the 49 studies testing belantamab mafodotin in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:
PrECOG, LLC. · Sites in United States
Ages 18–79
GlaxoSmithKline · Sites in United States, Argentina, Australia and 21 more countries
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
Universitätsklinikum Hamburg-Eppendorf · Sites in Germany
Ages 18+
By country, each count listing its studies:
belantamab mafodotin: first FDA approval 2020 (Blenrep), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
49 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 28 · Phase 2 29 · Phase 3 9
First in 2014; this study’s year is marked. 10 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 50 across the 49 interventional studies. Of the 11 that completed or were terminated, 8 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 49 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
42 studies in Multiple Myeloma by GlaxoSmithKline: 6 open now, 20 under way, 7 of them phase 3. Of 19 finished, 16 (84%) have results posted.
Among the 42 studies in Multiple Myeloma by GlaxoSmithKline, this one is the 30th largest by enrollment of the 40 interventional ones that give a count, is one of 4 that started in 2022, is one of 11 in phase 1/2, reaches primary completion later than 6 of the 19 other live ones, and was the 35th registered.
GlaxoSmithKline’s Multiple Myeloma studies by the year they started, since 2006.
4 of the studies testing belantamab mafodotin in Multiple Myeloma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05853965Universitätsklinikum Hamburg-EppendorfCombination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple Myeloma | 2027-04 |
| NCT03715478Canadian Myeloma Research GroupMulti-Center Study of GSK2857916 in Combination With Pomalidomide and Dex | 2027-06-01 |
| NCT05556798Memorial Sloan Kettering Cancer CenterA Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment | 2027-10 |
| NCT05208307Emory UniversityBelantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma | 2027-10-21 |
Add all 4 to your calendar (.ics) → With an account.
Among the 49 studies testing belantamab mafodotin in Multiple Myeloma, from their registry updates:
Among GlaxoSmithKline’s 42 in Multiple Myeloma:
This tab as a report to print or save as PDF → With an account.
The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with nirogacestat, lenalidomide, and dexamethasone, and to establish the recommended Phase 2 dose for combination treatment to explore in the cohort expansion (CE) phase in participants with RRMM. This study is a sub study of the Master protocol (NCT04126200).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Belantamab mafodotin · Drug: Nirogacestat · Drug: Lenalidomide · Drug: Dexamethasone
Belantamab mafodotin will be administered.
Also known as: GSK2857916
Nirogacestat will be administered.
Lenalidomide will be administered.
Dexamethasone will be administered.
DE Phase: Number of Participants With Dose Limiting Toxicities (DLTs)
Criteria for dose-limiting toxicity (DLT) included hematologic indicators such as Grade 3-5 febrile neutropenia and thrombocytopenia with bleeding. Non-hematologic criteria, excluding corneal toxicity, comprise Grade 3-5 toxicities, with exceptions for manageable nausea, vomiting, or diarrhea, controlled Grade 3 hypertension, and events linked to disease progression. Tumor lysis syndrome (TLS) of Grade 3 or 4, successfully managed within 7 days without end-organ damage, is considered. Corneal toxicity, assessed by the GSK corneal grading scale at Grade 4, is a DLT. Other organ-specific toxicities, notably liver toxicity meeting GSK stopping criteria, also qualify as DLT severity was graded using National Cancer Institute (NCI) - Common Terminology Criteria for Adverse Events (CTCAE) (version 5.0).
Time frame: Up to 28 days
DE Phase: Number of Participants With Adverse Events (AEs)
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.
Time frame: Up to 143 weeks
DE Phase: Number of Participants With Worst-Case Hematology Results by Maximum Grade Increase Post - Baseline Relative to Baseline
Blood samples were collected for the analysis of hematology parameters. The laboratory parameters were graded according to CTCAE version 5. Grade 1 (G1): mild; Grade 2 (G2): moderate; Grade 3 (G3): severe; Grade 4 (G4) life-threatening or disabling. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Any worst-case post baseline increase to G1, G2, G3, and G4 are presented. Baseline value was defined as the most recent, non-missing value from a local laboratory prior to the first dose of study treatment.
Time frame: Baseline (Day 1) and up to 143 weeks
DE Phase: Number of Participants With Worst-Case Chemistry Results by Maximum Grade Increase Post - Baseline Relative to Baseline
Blood samples were collected for the analysis of chemistry parameters. The laboratory parameters were graded according to CTCAE version 5. G1: mild; G2: moderate; G3: severe; Grade 4 (G4) life-threatening or disabling. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Any worst-case post baseline increase to G1, G2, G3, and G4 are presented. Baseline value was defined as the most recent, non-missing value from a local laboratory prior to the first dose of study treatment. CPK = creatine kinase. GGT = gamma glutamyl transferase.
Time frame: Baseline (Day 1) and up to 143 weeks
CE Phase: Overall Response Rate (ORR)
Overall Response Rate (ORR) was defined as the percentage of participants with a confirmed Partial Response (PR) or better as the best overall response (i.e., PR, Very Good Partial Response \[VGPR\], Complete Response \[CR\], and stringent Complete Response \[sCR\]), as assessed by the investigator per international myeloma working group (IMWG) (2016). PR is defined as ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to \<200 mg/24 h. VGPR is defined as serum and urine M-component detectable by immunofixation but not on electrophoresis OR ≥ 90% reduction in serum M-component plus urine M-component \<100 mg/24 h. CR is defined as negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND \<5% plasmacytomas in the bone marrow. sCR is defined as CR as above PLUS normal serum free light-chain (FLC) assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence.
Time frame: Up to 143 weeks
DE Phase: Overall Response Rate (ORR)
Overall Response Rate (ORR) was defined as the percentage of participants with a confirmed Partial Response (PR) or better as the best overall response (i.e., PR, Very Good Partial Response \[VGPR\], Complete Response \[CR\], and stringent Complete Response \[sCR\]), as assessed by the investigator per international myeloma working group (IMWG) (2016). PR is defined as ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to \<200 mg/24 h. VGPR is defined as serum and urine M-component detectable by immunofixation but not on electrophoresis OR ≥ 90% reduction in serum M-component plus urine M-component \<100 mg/24 h. CR is defined as negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND \<5% plasmacytomas in the bone marrow. sCR is defined as CR as above PLUS normal serum free light-chain (FLC) assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence.
Time frame: Up to 143 weeks
CE Phase: Clinical Benefit Rate (CBR)
Clinical benefit rate was defined as the percentage of participants with a confirmed minimal response (MR) or better according to the IMWG Response Criteria. MR is defined as \>= 25% but \< 49% reduction of serum M-protein and reduction in 24-hour urinary M-protein by 50-89%.
Time frame: Up to 143 weeks
DE Phase: Percentage of Participants Achieving Stringent Complete Response (SCR), Complete Response (CR), Very Good Partial Response (VGPR) and Partial Response (PR)
Partial Response \[PR\], Very Good Partial Response \[VGPR\], Complete Response \[CR\], and stringent Complete Response \[sCR\] as assessed by the investigator per IMWG (2016). PR defined as ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to \<200 mg/24 h. VGPR defined as serum and urine M-component detectable by immunofixation but not on electrophoresis OR ≥ 90% reduction in serum M-component plus urine M-component \<100 mg/24 h. CR defined as negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND \<5% plasmacytomas in the bone marrow. sCR defined as CR as above PLUS normal serum free light-chain (FLC) assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence.
Time frame: Up to 143 weeks
CE Phase: Percentage of Participants Achieving SCR, CR, VGPR and PR
Partial Response \[PR\], Very Good Partial Response \[VGPR\], Complete Response \[CR\], and stringent Complete Response \[sCR\] as assessed by the investigator per IMWG (2016). CR = negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND \<5% plasmacytomas in the bone marrow; sCR=stringent complete response, CR as above PLUS normal serum free light-chain (FLC) assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence; VGPR = serum and urine M-component detectable by immunofixation but not on electrophoresis OR ≥ 90% reduction in serum M-component plus urine M-component \<100 mg/24 h; PR = ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to \<200 mg/24 h.
Time frame: Up to 143 weeks
DE Phase: Plasma Concentrations of Belantamab Mafodotin Antibody-Drug Conjugate (ADC)
Blood samples were collected for PK analysis of belantamab mafodotin Antibody-Drug Conjugate (ADC). Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified timepoints.
Time frame: Predose, end of infusion (EOI), and 2 hours postdose on Cycle 1 Day 1; anytime samples at Cycle 1 Day 4, 8, 29; Predose and EOI on Day 1 of Cycle 2, 4, 6, 9, 12; Predose on Cycle 18 Day 1; and end of treatment (~143 weeks)
CE Phase: Plasma Concentrations of Belantamab Mafodotin Antibody-Drug Conjugate (ADC)
Blood samples were to be collected for PK analysis of Belantamab Mafodotin Antibody-Drug Conjugate (ADC).
Time frame: Up to 143 weeks
DE Phase: Plasma Concentration of Belantamab Mafodotin Total Antibody
Blood samples were collected for PK analysis of Belantamab mafodotin total antibody.
Time frame: Predose, end of infusion (EOI), and 2 hours postdose on Cycle 1 Day 1; anytime samples at Cycle 1 Day 4, 8, 29; Predose and EOI on Day 1 of Cycle 2, 4, 6, 9, 12; Predose on Cycle 18 Day 1; and end of treatment (~143 weeks)
CE Phase: Plasma Concentration of Belantamab Mafodotin Plasma Total Antibody
Blood samples were to be collected for PK analysis of Belantamab mafodotin plasma total antibody.
Time frame: Up to 143 weeks
DE Phase: Plasma Concentrations of Belantamab Mafodotin Cys- Monomethyl Auristatin-F (Cys-mcMMAF)
Blood samples were collected for PK analysis of belantamab mafodotin cys- monomethyl auristatin-F (cys-mcMMAF).
Time frame: Predose, end of infusion (EOI), and 2 hours postdose on Cycle 1 Day 1; anytime samples at Cycle 1 Day 4, 8, 29; Predose and EOI on Day 1 of Cycle 2, 4, 6, 9, 12; Predose on Cycle 18 Day 1; and end of treatment (~143 weeks)
CE Phase: Plasma Concentrations of Belantamab Mafodotin Cys- Monomethyl Auristatin-F (Cys-mcMMAF)
Blood samples were to be collected for PK analysis of Belantamab Mafodotin Cys- Monomethyl Auristatin-F (Cys-mcMMAF)
Time frame: Up to 143 weeks
DE Phase: Plasma Concentration of Nirogacestat When Administered in Combination With Belantamab Mafodotin
Blood samples were collected for PK analysis of Nirogacestat when administered orally in combination with belantamab mafodotin.
Time frame: Predose, 30 minutes, 1, 2, and 4 hours postdose on Cycle(C)1 Day -2; Predose on Day 1, 4, and 8 of C1; Predose, 30 minutes, 1, 2, and 4 hours postdose on C2 Day 1
CE Phase: Plasma Concentration of Nirogacestat When Administered in Combination With Belantamab Mafodotin
Blood samples were to be collected for PK analysis of Nirogacestat when administered orally in combination with belantamab mafodotin.
Time frame: Up to 143 weeks
DE Phase: Number of Participants With Post-baseline Positive Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin
Serum samples were collected for the analysis of the presence of ADAs using validated immunoassays. All samples were tested in screening assay, and positive samples were further characterized for antibody titers.
Time frame: Up to 143 weeks
CE Phase: Number of Participants With Post-baseline Positive ADAs Against Belantamab Mafodotin
Serum samples were to be collected for the analysis of the presence of ADAs using validated immunoassays. All samples were to be further tested in screening assay, and positive samples were further to be characterized for antibody titers.
Time frame: Up to 143 weeks
DE Phase: Titer of ADAs Against Belantamab Mafodotin
Serum samples were collected for the analysis of the presence of ADAs using validated immunoassays. All samples were to be further tested in screening assay, and positive samples were further to be characterized for antibody titers.
Time frame: Up to 143 weeks
CE Phase: Titer of ADAs Against Belantamab Mafodotin
Serum samples were to be collected for the analysis of the presence of ADAs using validated immunoassays. All samples were to be further tested in screening assay, and positive samples were further to be characterized for antibody titers.
Time frame: Up to 143 weeks
DE Phase: Number of Participants With Adverse Events of Special Interest (AESI)
An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Adverse Events of Special Interest (whether serious or non serious) were collected.
Time frame: Up to 143 weeks
CE Phase: Number of Participants With AESI
An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Adverse Events of Special Interest (whether serious or non serious) were to be collected.
Time frame: Up to 143 weeks
DE Phase: Number of Participants With Any Corneal Events by Maximum Grade as Per CTCAE Grade
The corneal events were graded according to CTCAE version 5. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant. Grade 4: Life-threatening consequences; Grade 5: Death related to AE. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Results are presented for number of participants with any corneal events by maximum grade as per CTCAE grade version (v) 5.0.
Time frame: Up to 143 weeks
CE Phase: Number of Participants With Any Corneal Events by Maximum Grade as Per CTCAE Grade
The corneal events were to be graded according to CTCAE version 5. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant. Grade 4: Life-threatening consequences; Grade 5: Death related to AE. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Results were to be presented for number of participants with any corneal events by maximum grade as per CTCAE grade version (v) 5.0.
Time frame: Up to 143 weeks
CE Phase: Progression-free Survival (PFS)
PFS is defined as the time from randomization until the earliest date of confirmed progressive disease (PD) per IMWG, or death due to any cause.
Time frame: Up to 143 weeks
CE Phase: Duration of Response (DoR)
DoR is defined as the time from first documented evidence or PR or better until progressive disease per IMWG or death due to progressive disease among participants who achieve confirmed partial response or better.
Time frame: Up to 143 weeks
CE Phase: Time to Response (TTR)
TTR is defined as the time between the date of randomization and the first documented evidence of response (PR or better), among participants who achieve a response (confirmed PR or better).
Time frame: Up to 143 weeks
CE Phase: Overall Survival (OS)
OS is defined as the time from randomization until death due to any cause.
Time frame: Up to 143 weeks
CE Phase: Number of Participants With AEs and SAEs
An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that; results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations judged by physician, is associated with liver injury and impaired liver function. AEs and SAEs were to be coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.
Time frame: Up to 143 weeks
CE Phase: Number of Participants With AEs Leading to Discontinuation
An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Number of participants with AEs leading to discontinuation were to be evaluated.
Time frame: Up to 143 weeks
CE Phase: Number of Participants With Dose Reduction or Delay
Number of participants with dose reduction or delay were to be evaluated.
Time frame: Up to 143 weeks
CE Phase: Number of Participants With Clinically Significant Changes in Hematology Lab Parameters
Blood samples were to be collected for the analysis of hematology parameters. The laboratory parameters were to be graded according to CTCAE version 5.0. Grade 1 (G1): mild; Grade 2 (G2): moderate; Grade 3 (G3: severe or medically significant; Grade 4: Life-threatening consequences; Grade 5: Death related to AE. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade.
Time frame: Up to 143 weeks
CE Phase: Number of Participants With Clinically Significant Changes in Clinical Chemistry Lab Parameters
Blood samples were to be collected for the analysis of chemistry parameters. The laboratory parameters were to be graded according to CTCAE version 5.0. G1: mild; G2: moderate; G3: severe or medically significant; Grade 4: Life-threatening consequences; Grade 5: Death related to AE. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade.
Time frame: Up to 143 weeks
This is a sub-study of the master study NCT04126200. The study was planned to include two phases - Dose Escalation (DE) and Cohort Expansion (CE) and no participants from this sub study were enrolled in CE phase as CE Phase was not initiated due to business strategic reason.
| Milestone | 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Lenalidomide + Dexamethasone | 1.0 mg/kg Belantamab Mafodotin + Nirogacestat + Lenalidomide + Dexamethasone |
|---|---|---|
| Started | 10 | 10 |
| Dlt evaluable population | 5 | 5 |
| Pharmacokinetic population | 10 | 10 |
| Safety population | 10 | 10 |
| Completed | 7 | 4 |
| Not completed | 3 | 6 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 2 |
| Withdrew: Ongoing at the time of analysis | 2 | 4 |
Criteria for dose-limiting toxicity (DLT) included hematologic indicators such as Grade 3-5 febrile neutropenia and thrombocytopenia with bleeding. Non-hematologic criteria, excluding corneal toxicity, comprise Grade 3-5 toxicities, with exceptions for manageable nausea, vomiting, or diarrhea, controlled Grade 3 hypertension, and events linked to disease progression. Tumor lysis syndrome (TLS) of Grade 3 or 4, successfully managed within 7 days without end-organ damage, is considered. Corneal toxicity, assessed by the GSK corneal grading scale at Grade 4, is a DLT. Other organ-specific toxicities, notably liver toxicity meeting GSK stopping criteria, also qualify as DLT severity was graded using National Cancer Institute (NCI) - Common Terminology Criteria for Adverse Events (CTCAE) (version 5.0).
| Participants | 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Lenalidomide + Dexamethasone | 1.0 mg/kg Belantamab Mafodotin + Nirogacestat + Lenalidomide + Dexamethasone |
|---|---|---|
| DE Phase: Number of Participants With Dose Limiting Toxicities (DLTs) | 1 | 2 |
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.
| Participants | 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Lenalidomide + Dexamethasone | 1.0 mg/kg Belantamab Mafodotin + Nirogacestat + Lenalidomide + Dexamethasone |
|---|---|---|
| DE Phase: Number of Participants With Adverse Events (AEs) | 9 | 10 |
Blood samples were collected for the analysis of hematology parameters. The laboratory parameters were graded according to CTCAE version 5. Grade 1 (G1): mild; Grade 2 (G2): moderate; Grade 3 (G3): severe; Grade 4 (G4) life-threatening or disabling. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Any worst-case post baseline increase to G1, G2, G3, and G4 are presented. Baseline value was defined as the most recent, non-missing value from a local laboratory prior to the first dose of study treatment.
| Participants | 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Lenalidomide + Dexamethasone | 1.0 mg/kg Belantamab Mafodotin + Nirogacestat + Lenalidomide + Dexamethasone |
|---|---|---|
| Eosinophilia, Increase to G1 | 4 | 5 |
| Eosinophilia, Increase to G2 | 0 | 0 |
| Eosinophilia, Increase to G3 | 0 | 0 |
| Eosinophilia, Increase to G4 | 0 | 0 |
| Anemia, Increase to G1 | 2 | 0 |
| Anemia, Increase to G2 | 2 | 2 |
| Anemia, Increase to G3 | 1 | 1 |
| Anemia, Increase to G4 | 0 | 0 |
| Hemoglobin increased, Increase to G1 | 0 | 0 |
| Hemoglobin increased, Increase to G2 | 0 | 0 |
| Hemoglobin increased, Increase to G3 | 0 | 0 |
| Hemoglobin increased, Increase to G4 | 0 | 0 |
| Lymphocyte count decreased, Increase to G1 | 0 | 0 |
| Lymphocyte count decreased, Increase to G2 | 2 | 3 |
| Lymphocyte count decreased, Increase to G3 | 1 | 4 |
| Lymphocyte count decreased, Increase to G4 | 3 | 0 |
| Lymphocyte count increased, Increase to G1 | 0 | 0 |
| Lymphocyte count increased, Increase to G2 | 0 | 1 |
| Lymphocyte count increased, Increase to G3 | 0 | 0 |
| Lymphocyte count increased, Increase to G4 | 0 | 0 |
| Neutrophil count decreased, Increase to G1 | 2 | 1 |
| Neutrophil count decreased, Increase to G2 | 2 | 1 |
| Neutrophil count decreased, Increase to G3 | 1 | 2 |
| Neutrophil count decreased, Increase to G4 | 1 | 2 |
| Platelet count decreased, Increase to G1 | 2 | 2 |
| Platelet count decreased, Increase to G2 | 2 | 2 |
| Platelet count decreased, Increase to G3 | 3 | 4 |
| Platelet count decreased, Increase to G4 | 0 | 1 |
| Leukocytosis, Increase to G1 | 0 | 0 |
| Leukocytosis, Increase to G2 | 0 | 0 |
| Leukocytosis, Increase to G3 | 0 | 0 |
| Leukocytosis, Increase to G4 | 0 | 0 |
| White blood cell decreased, Increase to G1 | 4 | 3 |
| White blood cell decreased, Increase to G2 | 1 | 3 |
| White blood cell decreased, Increase to G3 | 1 | 2 |
| White blood cell decreased, Increase to G4 | 1 | 0 |
Blood samples were collected for the analysis of chemistry parameters. The laboratory parameters were graded according to CTCAE version 5. G1: mild; G2: moderate; G3: severe; Grade 4 (G4) life-threatening or disabling. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Any worst-case post baseline increase to G1, G2, G3, and G4 are presented. Baseline value was defined as the most recent, non-missing value from a local laboratory prior to the first dose of study treatment. CPK = creatine kinase. GGT = gamma glutamyl transferase.
| Participants | 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Lenalidomide + Dexamethasone | 1.0 mg/kg Belantamab Mafodotin + Nirogacestat + Lenalidomide + Dexamethasone |
|---|---|---|
| Hypoglycemia, Increase to G1 | 0 | 0 |
| Hypoglycemia, Increase to G2 | 0 | 0 |
| Hypoglycemia, Increase to G3 | 0 | 0 |
| Hypoglycemia, Increase to G4 | 0 | 0 |
| Hypoalbuminemia, Increase to G1 | 2 | 3 |
| Hypoalbuminemia, Increase to G2 | 3 | 2 |
| Hypoalbuminemia, Increase to G3 | 0 | 0 |
| Hypoalbuminemia, Increase to G4 | 0 | 0 |
| Alkaline phosphatase increased, Increase to G1 | 0 | 3 |
| Alkaline phosphatase increased, Increase to G2 | 0 | 2 |
| Alkaline phosphatase increased, Increase to G3 | 0 | 0 |
| Alkaline phosphatase increased, Increase to G4 | 0 | 0 |
| Alanine aminotransferase increased, Increase to G1 | 5 | 4 |
| Alanine aminotransferase increased, Increase to G2 | 0 | 0 |
| Alanine aminotransferase increased, Increase to G3 | 0 | 1 |
| Alanine aminotransferase increased, Increase to G4 | 0 | 0 |
| Aspartate aminotransferase increased, Increase to G1 | 5 | 6 |
| Aspartate aminotransferase increased, Increase to G2 | 1 | 0 |
| Aspartate aminotransferase increased, Increase to G3 | 0 | 1 |
| Aspartate aminotransferase increased, Increase to G4 | 0 | 0 |
| Blood bilirubin increased, Increase to G1 | 1 | 1 |
| Blood bilirubin increased, Increase to G2 | 1 | 0 |
| Blood bilirubin increased, Increase to G3 | 0 | 0 |
| Blood bilirubin increased, Increase to G4 | 0 | 0 |
| CPK increased, Increase to G1 | 1 | 2 |
| CPK increased, Increase to G2 | 0 | 0 |
| CPK increased, Increase to G3 | 0 | 0 |
| CPK increased, Increase to G4 | 1 | 0 |
| Creatinine increased, Increase to G1 | 3 | 4 |
| Creatinine increased, Increase to G2 | 2 | 0 |
| Creatinine increased, Increase to G3 | 0 | 0 |
| Creatinine increased, Increase to G4 | 0 | 0 |
| GGT increased, Increase to G1 | 4 | 2 |
| GGT increased, Increase to G2 | 0 | 3 |
| GGT increased, Increase to G3 | 0 | 0 |
| GGT increased, Increase to G4 | 0 | 0 |
| Hyperkalemia, Increase to G1 | 1 | 0 |
| Hyperkalemia, Increase to G2 | 0 | 0 |
| Hyperkalemia, Increase to G3 | 0 | 0 |
| Hyperkalemia, Increase to G4 | 0 | 0 |
| Blood lactate dehydrogenase increased, Increase to G1 | 3 | 5 |
| Blood lactate dehydrogenase increased, Increase to G2 | 0 | 0 |
| Blood lactate dehydrogenase increased, Increase to G3 | 0 | 0 |
| Blood lactate dehydrogenase increased, Increase to G4 | 0 | 0 |
| Hypermagnesemia, Increase to G1 | 0 | 1 |
| Hypermagnesemia, Increase to G2 | 0 | 0 |
| Hypermagnesemia, Increase to G3 | 0 | 0 |
| Hypermagnesemia, Increase to G4 | 0 | 0 |
| Hypomagnesemia, Increase to G1 | 1 | 1 |
| Hypomagnesemia, Increase to G2 | 0 | 0 |
| Hypomagnesemia, Increase to G3 | 0 | 0 |
| Hypomagnesemia, Increase to G4 | 0 | 0 |
| Hypernatremia, Increase to G1 | 0 | 2 |
| Hypernatremia, Increase to G2 | 0 | 0 |
| Hypernatremia, Increase to G3 | 0 | 0 |
| Hypernatremia, Increase to G4 | 0 | 0 |
| Hypercalcemia, Increase to G1 | 0 | 0 |
| Hypercalcemia, Increase to G2 | 0 | 0 |
| Hypercalcemia, Increase to G3 | 1 | 0 |
| Hypercalcemia, Increase to G4 | 0 | 0 |
| Hypocalcemia, Increase to G1 | 5 | 5 |
| Hypocalcemia, Increase to G2 | 1 | 0 |
| Hypocalcemia, Increase to G3 | 0 | 0 |
| Hypocalcemia, Increase to G4 | 0 | 0 |
| Chronic Kidney Disease, Increase to G1 | 0 | 0 |
| Chronic Kidney Disease, Increase to G2 | 2 | 4 |
| Chronic Kidney Disease, Increase to G3 | 1 | 0 |
| Chronic Kidney Disease, Increase to G4 | 0 | 0 |
Overall Response Rate (ORR) was defined as the percentage of participants with a confirmed Partial Response (PR) or better as the best overall response (i.e., PR, Very Good Partial Response \[VGPR\], Complete Response \[CR\], and stringent Complete Response \[sCR\]), as assessed by the investigator per international myeloma working group (IMWG) (2016). PR is defined as ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to \<200 mg/24 h. VGPR is defined as serum and urine M-component detectable by immunofixation but not on electrophoresis OR ≥ 90% reduction in serum M-component plus urine M-component \<100 mg/24 h. CR is defined as negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND \<5% plasmacytomas in the bone marrow. sCR is defined as CR as above PLUS normal serum free light-chain (FLC) assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence.
No measurements were reported for this outcome.
Overall Response Rate (ORR) was defined as the percentage of participants with a confirmed Partial Response (PR) or better as the best overall response (i.e., PR, Very Good Partial Response \[VGPR\], Complete Response \[CR\], and stringent Complete Response \[sCR\]), as assessed by the investigator per international myeloma working group (IMWG) (2016). PR is defined as ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to \<200 mg/24 h. VGPR is defined as serum and urine M-component detectable by immunofixation but not on electrophoresis OR ≥ 90% reduction in serum M-component plus urine M-component \<100 mg/24 h. CR is defined as negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND \<5% plasmacytomas in the bone marrow. sCR is defined as CR as above PLUS normal serum free light-chain (FLC) assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence.
| Percentage of Participants | 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Lenalidomide + Dexamethasone | 1.0 mg/kg Belantamab Mafodotin + Nirogacestat + Lenalidomide + Dexamethasone |
|---|---|---|
| DE Phase: Overall Response Rate (ORR) | 40 (12.2 to 73.8) | 70 (34.8 to 93.3) |
Clinical benefit rate was defined as the percentage of participants with a confirmed minimal response (MR) or better according to the IMWG Response Criteria. MR is defined as \>= 25% but \< 49% reduction of serum M-protein and reduction in 24-hour urinary M-protein by 50-89%.
No measurements were reported for this outcome.
Partial Response \[PR\], Very Good Partial Response \[VGPR\], Complete Response \[CR\], and stringent Complete Response \[sCR\] as assessed by the investigator per IMWG (2016). PR defined as ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to \<200 mg/24 h. VGPR defined as serum and urine M-component detectable by immunofixation but not on electrophoresis OR ≥ 90% reduction in serum M-component plus urine M-component \<100 mg/24 h. CR defined as negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND \<5% plasmacytomas in the bone marrow. sCR defined as CR as above PLUS normal serum free light-chain (FLC) assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence.
| Percentage of Participants | 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Lenalidomide + Dexamethasone | 1.0 mg/kg Belantamab Mafodotin + Nirogacestat + Lenalidomide + Dexamethasone |
|---|---|---|
| Stringent Complete Response (sCR) | 10 | 30 |
| Complete Response (CR) | 0 | 0 |
| Very Good Partial Response (VGPR) | 20 | 10 |
| Partial Response (PR) | 10 | 30 |
Partial Response \[PR\], Very Good Partial Response \[VGPR\], Complete Response \[CR\], and stringent Complete Response \[sCR\] as assessed by the investigator per IMWG (2016). CR = negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND \<5% plasmacytomas in the bone marrow; sCR=stringent complete response, CR as above PLUS normal serum free light-chain (FLC) assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence; VGPR = serum and urine M-component detectable by immunofixation but not on electrophoresis OR ≥ 90% reduction in serum M-component plus urine M-component \<100 mg/24 h; PR = ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to \<200 mg/24 h.
No measurements were reported for this outcome.
Blood samples were collected for PK analysis of belantamab mafodotin Antibody-Drug Conjugate (ADC). Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified timepoints.
| Nanogram/ millilitre (ng/mL) | 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Lenalidomide + Dexamethasone | 1.0 mg/kg Belantamab Mafodotin + Nirogacestat + Lenalidomide + Dexamethasone |
|---|---|---|
| CYCLE 1 DAY 1, PRE-DOSE | 0.0 (0 to 0) | 0.0 (0 to 0) |
| CYCLE 1 DAY 1, END OF INFUSION | 12000.0 (6080 to 27700) | 27500.0 (8100 to 35900) |
| CYCLE 1 DAY 1, 2 HOURS | 12000.0 (6930 to 14900) | 23500.0 (8210 to 29700) |
| CYCLE 1 DAY 4, ANYTIME SAMPLE | 3315.0 (1270 to 4950) | 6180.0 (1580 to 9630) |
| CYCLE 1 DAY 8, ANYTIME SAMPLE | 1590.0 (665 to 1890) | 2550.0 (1020 to 5520) |
| CYCLE 1 DAY 29, ANYTIME SAMPLE | 0.0 (0 to 0) | 666.0 (NA to NA) |
| CYCLE 2 DAY 1, PRE-DOSE | 0.0 (0 to 663) | 0.0 (0 to 1820) |
| CYCLE 2 DAY 1, END OF INFUSION | 11700.0 (3370 to 15300) | 23200.0 (19000 to 93800) |
| CYCLE 4 DAY 1, PRE-DOSE | 0.0 (0 to 0) | 0.0 (0 to 2220) |
| CYCLE 4 DAY 1, END OF INFUSION | 17300.0 (7420 to 23100) | 18350.0 (6720 to 25200) |
| CYCLE 6 DAY 1, PRE-DOSE | 535.0 (0 to 830) | 0.0 (0 to 933) |
| CYCLE 6 DAY 1, END OF INFUSION | 15900.0 (11600 to 31400) | 18400.0 (10600 to 22600) |
| CYCLE 9 DAY 1, PRE-DOSE | 884.5 (659 to 1110) | 0.0 (0 to 816) |
| CYCLE 9 DAY 1, END OF INFUSION | 13450.0 (12900 to 14000) | 16550.0 (12300 to 38800) |
| CYCLE 12 DAY 1, PRE-DOSE | 1024.0 (598 to 1450) | — |
| CYCLE 12 DAY 1, END OF INFUSION | 12250.0 (12100 to 12400) | — |
| CYCLE 18 DAY 1, PRE-DOSE | 1760.0 (NA to NA) | — |
| END OF TREATMENT (~143 weeks) | 0.0 (0 to 890) | 334.0 (0 to 3610) |
Blood samples were to be collected for PK analysis of Belantamab Mafodotin Antibody-Drug Conjugate (ADC).
No measurements were reported for this outcome.
Blood samples were collected for PK analysis of Belantamab mafodotin total antibody.
| Nanogram/ millilitre (ng/mL) | 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Lenalidomide + Dexamethasone | 1.0 mg/kg Belantamab Mafodotin + Nirogacestat + Lenalidomide + Dexamethasone |
|---|---|---|
| CYCLE 1 DAY 1, PRE-DOSE | 0.0 (0 to 1000) | 0.0 (0 to 0) |
| CYCLE 1 DAY 1, END OF INFUSION | 8245.0 (6310 to 32900) | 20700.0 (8090 to 92900) |
| CYCLE 1 DAY 1, 2 HOURS | 8310.0 (6940 to 21800) | 21300.0 (8140 to 32800) |
| CYCLE 1 DAY 4, ANYTIME SAMPLE | 4055.0 (2090 to 14800) | 7715.0 (2330 to 13300) |
| CYCLE 1 DAY 8, ANYTIME SAMPLE | 2395.0 (1550 to 4730) | 5670.0 (1800 to 6660) |
| CYCLE 1 DAY 29, ANYTIME SAMPLE | 0.0 (0 to 1300) | 1560.0 (NA to NA) |
| CYCLE 2 DAY 1, PRE-DOSE | 0.0 (0 to 2530) | 1270.0 (0 to 2600) |
| CYCLE 2 DAY 1, END OF INFUSION | 11100.0 (2010 to 15000) | 20900.0 (11100 to 25800) |
| CYCLE 4 DAY 1, PRE-DOSE | 0.0 (0 to 2140) | 1795.0 (0 to 5040) |
| CYCLE 4 DAY 1, END OF INFUSION | 14000.0 (12200 to 21900) | 15500.0 (8480 to 20000) |
| CYCLE 6 DAY 1, PRE-DOSE | 3620.0 (511 to 4990) | 1180.0 (0 to 2340) |
| CYCLE 6 DAY 1, END OF INFUSION | 8830.0 (5240 to 43400) | 15800.0 (10700 to 17000) |
| CYCLE 9 DAY 1, PRE-DOSE | 3195.0 (1540 to 4850) | 1575.0 (0 to 2010) |
| CYCLE 9 DAY 1, END OF INFUSION | 13600.0 (10100 to 17100) | 11850.0 (11200 to 17900) |
| CYCLE 12 DAY 1, PRE-DOSE | 4850.0 (3150 to 6550) | — |
| CYCLE 12 DAY 1, END OF INFUSION | 15400.0 (15100 to 15700) | — |
| CYCLE 18 DAY 1, PRE-DOSE | 5110.0 (NA to NA) | — |
| END OF TREATMENT (~143 weeks) | 0.0 (0 to 2070) | 1685.0 (1110 to 5910) |
Blood samples were to be collected for PK analysis of Belantamab mafodotin plasma total antibody.
No measurements were reported for this outcome.
Blood samples were collected for PK analysis of belantamab mafodotin cys- monomethyl auristatin-F (cys-mcMMAF).
| Picogram / millilitre (pg/mL) | 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Lenalidomide + Dexamethasone | 1.0 mg/kg Belantamab Mafodotin + Nirogacestat + Lenalidomide + Dexamethasone |
|---|---|---|
| CYCLE 1 DAY 1, PRE-DOSE | 0.00 (0.0 to 0.0) | 0.00 (0.0 to 0.0) |
| CYCLE 1 DAY 1, END OF INFUSION | 86.45 (0.0 to 388.0) | 159.00 (106.0 to 515.0) |
| CYCLE 1 DAY 1, 2 HOURS | 130.00 (55.8 to 369.0) | 262.50 (105.0 to 492.0) |
| CYCLE 1 DAY 4, ANYTIME SAMPLE | 149.00 (69.7 to 410.0) | 247.00 (139.0 to 908.0) |
| CYCLE 1 DAY 8, ANYTIME SAMPLE | 0.00 (0.0 to 165.0) | 88.80 (0.0 to 265.0) |
| CYCLE 1 DAY 29, ANYTIME SAMPLE | 0.00 (NA to NA) | 0.00 (NA to NA) |
| CYCLE 2 DAY 1, PRE-DOSE | 0.00 (0.0 to 0.0) | 0.00 (0.0 to 0.0) |
| CYCLE 2 DAY 1, END OF INFUSION | 118.50 (84.0 to 177.0) | 163.00 (95.6 to 229.0) |
| CYCLE 4 DAY 1, PRE-DOSE | 0.00 (0.0 to 0.0) | 0.00 (0.0 to 0.0) |
| CYCLE 4 DAY 1, END OF INFUSION | 127.00 (95.9 to 161.0) | 83.15 (50.3 to 185.0) |
| CYCLE 6 DAY 1, PRE-DOSE | 0.00 (0.0 to 0.0) | 0.00 (0.0 to 0.0) |
| CYCLE 6 DAY 1, END OF INFUSION | 108.00 (53.0 to 395.0) | 166.00 (115.0 to 183.0) |
| CYCLE 9 DAY 1, PRE-DOSE | 0.00 (0.0 to 0.0) | 0.00 (0.0 to 0.0) |
| CYCLE 9 DAY 1, END OF INFUSION | 88.00 (80.3 to 95.7) | 81.00 (0.0 to 137.0) |
| CYCLE 12 DAY 1, PRE-DOSE | 0.00 (0.0 to 0.0) | — |
| CYCLE 12 DAY 1, END OF INFUSION | 111.25 (67.5 to 155.0) | — |
| CYCLE 18 DAY 1, PRE-DOSE | 0.00 (NA to NA) | — |
| END OF TREATMENT (~143 weeks) | 0.00 (0.0 to 0.0) | 0.00 (0.0 to 0.0) |
Blood samples were to be collected for PK analysis of Belantamab Mafodotin Cys- Monomethyl Auristatin-F (Cys-mcMMAF)
No measurements were reported for this outcome.
Blood samples were collected for PK analysis of Nirogacestat when administered orally in combination with belantamab mafodotin.
| ng/mL | 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Lenalidomide + Dexamethasone | 1.0 mg/kg Belantamab Mafodotin + Nirogacestat + Lenalidomide + Dexamethasone |
|---|---|---|
| CYCLE 1 DAY -2, PRE-DOSE | 0.00 (0.0 to 0.0) | 0.00 (0.0 to 0.0) |
| CYCLE 1 DAY-2, 30 MINUTES | 101.60 (0.0 to 634.0) | 215.55 (0.0 to 1200.0) |
| CYCLE 1 DAY-2, 1 HOUR | 433.00 (0.0 to 933.0) | 431.00 (6.6 to 894.0) |
| CYCLE 1 DAY-2, 2 HOURS | 284.50 (65.3 to 1540.0) | 329.00 (114.0 to 1460.0) |
| CYCLE 1 DAY-2, 4 HOURS | 139.00 (24.8 to 799.0) | 169.50 (96.4 to 719.0) |
| CYCLE 1 DAY 1, PRE-DOSE | 125.00 (32.1 to 421.0) | 89.85 (43.4 to 1130.0) |
| CYCLE 1 DAY 4, PRE-DOSE | 244.00 (63.8 to 972.0) | 199.00 (88.6 to 1760.0) |
| CYCLE 1 DAY 8, PRE-DOSE | 231.00 (61.2 to 1040.0) | 164.00 (97.8 to 2750.0) |
| CYCLE 2 DAY 1, PRE-DOSE | 126.00 (0.0 to 1200.0) | 140.55 (11.3 to 568.0) |
| CYCLE 2 DAY 1, 30 MINUTES | 192.00 (0.9 to 1050.0) | 92.85 (3.9 to 826.0) |
| CYCLE 2 DAY 1, 1 HOUR | 500.00 (57.7 to 1080.0) | 138.00 (11.1 to 787.0) |
| CYCLE 2 DAY 1, 2 HOURS | 649.00 (49.6 to 2980.0) | 417.50 (17.6 to 1640.0) |
| CYCLE 2 DAY 1, 4 HOURS | 311.00 (49.7 to 2770.0) | 406.00 (144.0 to 1480.0) |
Blood samples were to be collected for PK analysis of Nirogacestat when administered orally in combination with belantamab mafodotin.
No measurements were reported for this outcome.
Serum samples were collected for the analysis of the presence of ADAs using validated immunoassays. All samples were tested in screening assay, and positive samples were further characterized for antibody titers.
| Participants | 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Lenalidomide + Dexamethasone | 1.0 mg/kg Belantamab Mafodotin + Nirogacestat + Lenalidomide + Dexamethasone |
|---|---|---|
| DE Phase: Number of Participants With Post-baseline Positive Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin | 0 | 0 |
Serum samples were to be collected for the analysis of the presence of ADAs using validated immunoassays. All samples were to be further tested in screening assay, and positive samples were further to be characterized for antibody titers.
No measurements were reported for this outcome.
Serum samples were collected for the analysis of the presence of ADAs using validated immunoassays. All samples were to be further tested in screening assay, and positive samples were further to be characterized for antibody titers.
No measurements were reported for this outcome.
Serum samples were to be collected for the analysis of the presence of ADAs using validated immunoassays. All samples were to be further tested in screening assay, and positive samples were further to be characterized for antibody titers.
No measurements were reported for this outcome.
An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Adverse Events of Special Interest (whether serious or non serious) were collected.
| Participants | 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Lenalidomide + Dexamethasone | 1.0 mg/kg Belantamab Mafodotin + Nirogacestat + Lenalidomide + Dexamethasone |
|---|---|---|
| DE Phase: Number of Participants With Adverse Events of Special Interest (AESI) | 9 | 10 |
An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Adverse Events of Special Interest (whether serious or non serious) were to be collected.
No measurements were reported for this outcome.
The corneal events were graded according to CTCAE version 5. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant. Grade 4: Life-threatening consequences; Grade 5: Death related to AE. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Results are presented for number of participants with any corneal events by maximum grade as per CTCAE grade version (v) 5.0.
| Participants | 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Lenalidomide + Dexamethasone | 1.0 mg/kg Belantamab Mafodotin + Nirogacestat + Lenalidomide + Dexamethasone |
|---|---|---|
| Grade 1 | 2 | 4 |
| Grade 2 | 1 | 1 |
| Grade 3 | 0 | 0 |
| Grade 4 | 0 | 0 |
| Grade 5 | 0 | 0 |
The corneal events were to be graded according to CTCAE version 5. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant. Grade 4: Life-threatening consequences; Grade 5: Death related to AE. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Results were to be presented for number of participants with any corneal events by maximum grade as per CTCAE grade version (v) 5.0.
No measurements were reported for this outcome.
PFS is defined as the time from randomization until the earliest date of confirmed progressive disease (PD) per IMWG, or death due to any cause.
No measurements were reported for this outcome.
DoR is defined as the time from first documented evidence or PR or better until progressive disease per IMWG or death due to progressive disease among participants who achieve confirmed partial response or better.
No measurements were reported for this outcome.
TTR is defined as the time between the date of randomization and the first documented evidence of response (PR or better), among participants who achieve a response (confirmed PR or better).
No measurements were reported for this outcome.
OS is defined as the time from randomization until death due to any cause.
No measurements were reported for this outcome.
An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that; results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations judged by physician, is associated with liver injury and impaired liver function. AEs and SAEs were to be coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.
No measurements were reported for this outcome.
An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Number of participants with AEs leading to discontinuation were to be evaluated.
No measurements were reported for this outcome.
Number of participants with dose reduction or delay were to be evaluated.
No measurements were reported for this outcome.
Blood samples were to be collected for the analysis of hematology parameters. The laboratory parameters were to be graded according to CTCAE version 5.0. Grade 1 (G1): mild; Grade 2 (G2): moderate; Grade 3 (G3: severe or medically significant; Grade 4: Life-threatening consequences; Grade 5: Death related to AE. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade.
No measurements were reported for this outcome.
Blood samples were to be collected for the analysis of chemistry parameters. The laboratory parameters were to be graded according to CTCAE version 5.0. G1: mild; G2: moderate; G3: severe or medically significant; Grade 4: Life-threatening consequences; Grade 5: Death related to AE. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade.
No measurements were reported for this outcome.
Collected over All cause mortality, Non- Serious Adverse Events (non-SAEs) and Serious Adverse Events (SAEs) were collected upto approximately 143 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Lenalidomide + Dexamethasone | 4/10 (40%) | 5/10 (50%) | 8/10 (80%) |
| 1.0 mg/kg Belantamab Mafodotin + Nirogacestat + Lenalidomide + Dexamethasone | 3/10 (30%) | 8/10 (80%) | 10/10 (100%) |
| Event | 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Lenalidomide + Dexamethasone | 1.0 mg/kg Belantamab Mafodotin + Nirogacestat + Lenalidomide + Dexamethasone |
|---|---|---|
| PneumoniaInfections and infestations | 3/10 | 1/10 |
| DiarrhoeaGastrointestinal disorders | 2/10 | 2/10 |
| AstheniaGeneral disorders | 0/10 | 2/10 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/10 | 0/10 |
| Cardiac amyloidosisCardiac disorders | 0/10 | 1/10 |
| Cardiac failureCardiac disorders | 0/10 | 1/10 |
| NauseaGastrointestinal disorders | 0/10 | 1/10 |
| StomatitisGastrointestinal disorders | 0/10 | 1/10 |
| VomitingGastrointestinal disorders | 1/10 | 1/10 |
| Drug-induced liver injuryHepatobiliary disorders | 0/10 | 1/10 |
| Event | 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Lenalidomide + Dexamethasone | 1.0 mg/kg Belantamab Mafodotin + Nirogacestat + Lenalidomide + Dexamethasone |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 6/10 | 2/10 |
| Platelet count decreasedInvestigations | 1/10 | 6/10 |
| HypokalaemiaMetabolism and nutrition disorders | 2/10 | 6/10 |
| HypophosphataemiaMetabolism and nutrition disorders | 2/10 | 6/10 |
| NauseaGastrointestinal disorders | 2/10 | 5/10 |
| NeutropeniaBlood and lymphatic system disorders | 4/10 | 1/10 |
| ThrombocytopeniaBlood and lymphatic system disorders | 4/10 | 3/10 |
| Vision blurredEye disorders | 1/10 | 4/10 |
| FatigueGeneral disorders | 3/10 | 4/10 |
| Neutrophil count decreasedInvestigations | 0/10 | 4/10 |
| Age, Continuous(YEARS) | 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Lenalidomide + Dexamethasone | 1.0 mg/kg Belantamab Mafodotin + Nirogacestat + Lenalidomide + Dexamethasone | Total |
|---|---|---|---|
| Mean | 60.1 ± 10.55 | 67.1 ± 7.23 | 63.6 ± 9.51 |
| Sex: Female, Male(Participants) | 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Lenalidomide + Dexamethasone | 1.0 mg/kg Belantamab Mafodotin + Nirogacestat + Lenalidomide + Dexamethasone | Total |
|---|---|---|---|
| Female | 6 | 6 | 12 |
| Male | 4 | 4 | 8 |
| Race (NIH/OMB)(Participants) | 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Lenalidomide + Dexamethasone | 1.0 mg/kg Belantamab Mafodotin + Nirogacestat + Lenalidomide + Dexamethasone | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 2 | 5 | 7 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 1 |
| White | 7 | 5 | 12 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf.
Ran from Jul 2022 to primary completion in Apr 2025, 32 months.
Results were first posted in Jun 2026, 1 year 1 month after primary completion.
Of 98 industry-sponsored phase 1/2 interventional studies under Multiple Myeloma, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 90. This study's 32 months is below that.
Counting every sponsor, half of 201 studies reached it within 65 months; a quarter within 44 and three quarters within 92.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Belantamab mafodotin · Nirogacestat · Lenalidomide · Dexamethasone